MeiraGTx Holdings (MGTX) Non-Current Deffered Revenue (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Non-Current Deffered Revenue came in at $65.1 million in Q4 2025, up 13.1% YoY from $57.6 million in Q4 2024, and up 1.42% on a QoQ basis from $64.2 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Non-Current Deffered Revenue data on file, last reported at $65.1 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue rose 13.1% year-over-year to $65.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $65.1 million (up 13.1% YoY) and the FY2025 annual result came in at $65.1 million, up 13.1% from the prior year.
- Non-Current Deffered Revenue climbed to $65.1 million in Q4 2025, from $64.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $65.1 million in Q4 2025 to a low of $15.5 million in Q3 2022.
- A 5-year average of $42.2 million and a median of $41.2 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue tumbled 52.33% — and 2024, when it surged 153.99%.
- Tracing MGTX's Non-Current Deffered Revenue over 5 years: stood at $43.0 million in 2021, then tumbled by 36.26% to $27.4 million in 2022, then rose by 23.99% to $34.0 million in 2023, then surged by 69.26% to $57.6 million in 2024, then advanced by 13.1% to $65.1 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $65.1 million (Q4 2025), $64.2 million (Q3 2025), and $63.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 11.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.10 Mn |
| Dec 31, 2025 | 65.12 Mn |
| Sep 30, 2025 | 64.21 Mn |
| Jun 30, 2025 | 63.04 Mn |
| Mar 31, 2025 | 59.62 Mn |
| Dec 31, 2024 | 57.58 Mn |
| Sep 30, 2024 | 58.90 Mn |
| Jun 30, 2024 | 53.76 Mn |
| Mar 31, 2024 | 53.33 Mn |
| Dec 31, 2023 | 34.02 Mn |
| Sep 30, 2023 | 23.19 Mn |
| Jun 30, 2023 | 25.36 Mn |
| Mar 31, 2023 | 26.43 Mn |
| Dec 31, 2022 | 27.44 Mn |
| Sep 30, 2022 | 15.49 Mn |
| Jun 30, 2022 | 21.34 Mn |
| Mar 31, 2022 | 37.28 Mn |
| Dec 31, 2021 | 43.05 Mn |
| Sep 30, 2021 | 32.49 Mn |
| Jun 30, 2021 | 39.33 Mn |